revolutionary RNA-based therapies capable of endogenously regenerating the human heart.
precise targeting and controlled modulation of genetic pathways involved in cardiac cell proliferation and cardiac tissue repair.
advanced laboratory models of cardiac disease that accurately replicate key features of heart conditions.
Summa is led by a diverse and skilled team, uniting extensive experience in RNA biology, cutting-edge technology, and entrepreneurship. We believe in the power of collaboration, innovation, and dedication.
Alongside us, the company is supported by trusted advisors.